| 24.53 0.74 (3.11%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.66 | 1-year : | 34.68 |
| Resists | First : | 26.25 | Second : | 29.7 |
| Pivot price | 26.47  |
|||
| Supports | First : | 20.67 | Second : | 17.19 |
| MAs | MA(5) : | 23.97 |
MA(20) : | 26.56 |
| MA(100) : | 27.98 |
MA(250) : | 31.16 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 36.1 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 42.47 | Low : | 20.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARWR ] has closed above bottom band by 31.5%. Bollinger Bands are 112.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.94 - 24.05 | 24.05 - 24.16 |
| Low: | 23.07 - 23.2 | 23.2 - 23.32 |
| Close: | 23.58 - 23.78 | 23.78 - 23.97 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Thu, 07 Dec 2023
Arrowhead Pharma: Transition To Commercialization (NASDAQ:ARWR) - Seeking Alpha
Fri, 01 Dec 2023
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript - Yahoo Finance
Fri, 01 Dec 2023
Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed - Seeking Alpha
Fri, 01 Dec 2023
Premarket Mover: Arrowhead Pharmaceuticals Inc (ARWR) Up 2.12% - InvestorsObserver
Wed, 29 Nov 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results - Business Wire
Wed, 29 Nov 2023
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 70.7 (%) |
| Shares Short | 7,880 (K) |
| Shares Short P.Month | 7,130 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.52 |
| Profit Margin | -85.3 % |
| Operating Margin | -673 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -59.4 % |
| Qtrly Rev. Growth | -49 % |
| Gross Profit (p.s.) | 2.26 |
| Sales Per Share | 2.24 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -12.78 |
| PEG Ratio | -1 |
| Price to Book value | 9.69 |
| Price to Sales | 10.94 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|